KPTI

Karyopharm Therapeutics Inc

• TipRanks·3d ago

  Karyopharm price target lowered to $16 from $23 at RBC Capital

• Dow Jones·03/30 18:05

  Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler

• Benzinga·03/30 17:55

  Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8

• TipRanks·03/30 11:49

  Piper Sandler Releases a Buy Rating on Karyopharm Therapeutics (KPTI)

• TipRanks·03/30 11:31

  Karyopharm price target lowered to $8 from $12 at Piper Sandler

• Reuters·03/30 07:35

  U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

• Reuters·03/30 04:21

  KARYOPHARM THERAPEUTICS INC <KPTI.O>: PIPER SANDLER CUTS TARGET PRICE TO $8 FROM $12

• TipRanks·03/27 13:06

  Karyopharm Strengthens Liquidity With New Equity Financing

• NASDAQ·03/27 12:49

  Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

• Reuters·03/27 12:05

  Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement

• Seeking Alpha·03/26 11:01

  Karyopharm: Putting The Phase 3 Trial In Context

• NASDAQ·03/25 12:35

  Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

• Dow Jones·03/25 12:32

  Karyopharm Therapeutics Is Maintained at Outperform by Baird

• Dow Jones·03/25 12:32

  Karyopharm Therapeutics Price Target Cut to $15.00/Share From $21.00 by Baird

• Benzinga·03/25 12:22

  Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15